ÌÇÐÄÆƽâ°æ

Skip to main content

Percentage of drugs approved by the U.S. Center for Drug Evaluation and Research (CDER) in 2025 that met select key measurements

Key measurements of U.S. CDER drug approvals in 2025

Last update:
Jan 30, 2026
Author:
ÌÇÐÄÆƽâ°æ Research Department
Region:
United States
Survey time period:
From 01/01/2025 to 31/12/2025

Related insights

Number of novel drugs approved annually by CDER 2008-2025
USA
Personalized medicines as percent of new molecular entities 2014-2024
USA
Share of newly FDA approved personalized medicines in 2024, by indicated treatment
USA
Rate of approval for Indian pharma ANDA by U.S. FDA 2017-2019
IND
Patent filing percentage after FDA approval among top selling U.S. until 2024
USA
Share of new orphan drugs available in Europe in 2025, by country
U.S. development Phase success rates for rare and common disease drugs 2011-2020
USA
U.S. drug development phase I to approval success rates 2011-2020 by disease area
USA
Number of biosimilars approved by FDA 2015-2025
USA
Share of new medicines available in Europe in 2025, by country
Clinical development success rate in novel cardiovascular drugs U.S. 2008-2019
USA
U.S. drug development phase success rates 2011-2020
USA
FDA breakthrough drug designations by therapy area 2025
Worldwide
FDA approved orphan drugs with non-orphan indications 1983-2018
USA
U.S. drug development Phase success rates, by drug classification 2011-2020
USA
Share of new non-oncology orphan medicines available in Europe in 2025, by country
U.S. development phase success rates for drugs with and without biomarkers 2011-2020
USA
Oncology or orphan drug share in approved new active substances 2015-2023
Impact of CROs on drug development industry 2025
CAN
Number of orphan designations accepted in the U.S. 2003-2025
USA
Share of new oncology medicines available in Europe in 2025, by country
Percentage of global pharmaceutical sales by technology 2016-2030
Worldwide
U.S. approval of pharma companies' COVID-19 vaccine development handling 2021
USA
U.S. development Phase success rates for oncology and non oncology drugs 2011-2020
USA
Number of drug approval applications submitted in China 2018-2024
CHN
U.S. drug development phase II success rates 2011-2020, by disease area
USA
U.S. drug development phase III success rates 2011-2020, by disease area
USA
Number of approved ANDAs in U.S. 2009-2023
USA
Canadian drug market sales contribution of patented drugs 1990-2024
CAN
Number of Indian ANDA approvals by the U.S. FDA 2017-2019
IND
Number of drug approvals for rare diseases 1970-2010
USA
Share of new combination therapies available in Europe in 2025, by country
Canada 's global sales share of patented drugs 2005-2023
Worldwide
Share of U.S. adults who approve pharmaceutical companies' drug price handling 2021
USA
Pharmaceutical industry: global breakdown in the sale of new drugs 2004-2024
Worldwide
Clinical trial success rates by therapeutic area 2020
USA
FDA approved orphan drugs 1983-2018, by approval sequence
USA
Number of approved drug evaluation applications in China 2021, by type of application
CHN
Number of NDA of innovative drugs approved in China 2018-2024
CHN
Investors expectations for CDMOs valuation 2025-2026
Worldwide
Origin of new drugs licensed or acquired, 2014-2018, by company size
USA
Personalized medicine in development by type 2015
USA
Number of therapies approved globally 2020-2024, by modality
Worldwide
Share of sales attributable to new active substances launched 2018-2022 by country
Worldwide
Number of FDA approved NMEs, 2009-2018, by size of drug owner
USA
CDMO market share worldwide 2025, by company
Worldwide
Projected share of pipelines with AI-discovered targets in biopharma 2025-2035
USA
VR and AR medical devices approved by the FDA in the U.S. 2015-2025
USA
Clinical trials – statistics & facts
Worldwide
Pharmaceutical industry in the United States
USA
We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch